Should I buy or sell Yield10 Bioscience stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" YTEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YTEN, but not buy additional shares or sell existing shares. View YTEN analyst ratings or view top-rated stocks .

What is Yield10 Bioscience's stock price target for 2024?

3 Wall Street research analysts have issued 1-year target prices for Yield10 Bioscience's shares. Their YTEN share price targets range from $3.00 to $4.00. On average, they expect the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 1,272.5% from the stock's current price. View analysts price targets for YTEN or view top-rated stocks among Wall Street analysts .

How have YTEN shares performed in 2024?

Yield10 Bioscience's stock was trading at $0.2393 at the start of the year. Since then, YTEN stock has increased by 6.6% and is now trading at $0.2550. View the best growth stocks for 2024 here .

Are investors shorting Yield10 Bioscience?

Yield10 Bioscience saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 940,900 shares, an increase of 292.2% from the March 15th total of 239,900 shares. Based on an average daily trading volume, of 4,820,000 shares, the days-to-cover ratio is presently 0.2 days. View Yield10 Bioscience's Short Interest .

When is Yield10 Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our YTEN earnings forecast .

How were Yield10 Bioscience's earnings last quarter?

Yield10 Bioscience, Inc. (NASDAQ:YTEN) announced its quarterly earnings data on Tuesday, November, 9th. The specialty chemicals company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.16. The specialty chemicals company earned $0.09 million during the quarter, compared to analysts' expectations of $0.22 million. During the same quarter in the prior year, the business earned ($0.87) EPS.

When did Yield10 Bioscience's stock split?

Yield10 Bioscience shares reverse split on Thursday, January 16th 2020. The 1-40 reverse split was announced on Wednesday, January 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Yield10 Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Yield10 Bioscience investors own include KushCo (KSHB) , OPKO Health (OPK) , T2 Biosystems (TTOO) , FuelCell Energy (FCEL) , TherapeuticsMD (TXMD) , Viking Therapeutics (VKTX) , Rigel Pharmaceuticals (RIGL) , Advanced Micro Devices (AMD) .

How do I buy shares of Yield10 Bioscience?

Shares of YTEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:YTEN

Yield10 Bioscience (YTEN) Stock Price, News & Analysis

→ Did you know you can now trade Bitcoin in your regular brokerage account? (From DTI) (Ad)

Free YTEN Stock Alerts

$0.26

-0.02 (-7.27%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.25
▼
$0.28
50-Day Range: $0.22
▼
$0.43
52-Week Range: $0.18
▼
$3.29

Volume: 283,450 shs
Average Volume: 4.18 million shs
Market Capitalization: $3.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.50

Get Yield10 Bioscience alerts:

Yield10 Bioscience MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 1,272.5% Upside
$3.50 Price Target
Short Interest: Bearish
6.11% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.55 out of 5 stars

3.2

Analyst's Opinion

Consensus Rating
Yield10 Bioscience has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Yield10 Bioscience has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.11% of the outstanding shares of Yield10 Bioscience have been sold short.
Short Interest Ratio / Days to Cover
Yield10 Bioscience has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Yield10 Bioscience has recently increased by 292.21%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Yield10 Bioscience does not currently pay a dividend.
Dividend Growth
Yield10 Bioscience does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for YTEN.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Yield10 Bioscience this week, compared to 1 article on an average week.
Search Interest
10 people have searched for YTEN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
6 people have added Yield10 Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Yield10 Bioscience insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.10% of the stock of Yield10 Bioscience is held by insiders.
Percentage Held by Institutions
Only 4.91% of the stock of Yield10 Bioscience is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Yield10 Bioscience is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Yield10 Bioscience is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Yield10 Bioscience Stock (NASDAQ:YTEN)

Yield10 Bioscience, Inc. operates as agricultural bioscience company in the United States. The company primarily focus on production of low carbon products through processing Camelina seeds. Its products include Camelina oil for low carbon biofuel feedstock; Omega-3 oils for nutrition; and PHA bioplastics for biodegradable zero waste packaging solutions. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts.

YTEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

YTEN Stock News Headlines

April 19, 2024 | americanbankingnews.com

Yield10 Bioscience (NASDAQ:YTEN) Stock Price Passes Above 200 Day Moving Average of $0.27

April 11, 2024 | americanbankingnews.com

Yield10 Bioscience (NASDAQ:YTEN) Shares Cross Above 200-Day Moving Average of $0.27

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 11, 2024 | americanbankingnews.com

Short Interest in Yield10 Bioscience, Inc. (NASDAQ:YTEN) Expands By 292.2%

April 5, 2024 | finance.yahoo.com

Yield10 Bioscience, Inc. (NASDAQ:YTEN) Q4 2023 Earnings Call Transcript

April 3, 2024 | markets.businessinsider.com

Hold Recommendation on Yield10 Bioscience Amid Commercialization and Capital Uncertainties

April 2, 2024 | finance.yahoo.com

Q4 2023 Yield10 Bioscience Inc Earnings Call

April 1, 2024 | investorplace.com

YTEN Stock Earnings: Yield10 Bioscience Beats EPS for Q4 2023

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 1, 2024 | benzinga.com

Yield10 Bioscience: Q4 Earnings Insights

April 1, 2024 | globenewswire.com

Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

March 28, 2024 | globenewswire.com

Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024

March 26, 2024 | globenewswire.com

Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada

March 23, 2024 | stockhouse.com

USDA-APHIS Determines that Yield10 Bioscience's Omega-3 Camelina Varieties May Be Planted and Bred in the United States

March 21, 2024 | markets.businessinsider.com

Dow Jumps 200 Points; US Weekly Jobless Claims Fall

March 21, 2024 | markets.businessinsider.com

USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States

March 21, 2024 | msn.com

Yield10 stock soars 120% on USDA okay for Camelina planting

March 21, 2024 | finance.yahoo.com

USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States

March 21, 2024 | investorplace.com

Why Is Yield10 (YTEN) Stock Up 117% Today?

March 21, 2024 | globenewswire.com

USDA-APHIS Determines that Yield10 Bioscience's Omega-3 Camelina Varieties May Be Planted and Bred in the United States

March 10, 2024 | barrons.com

Yield10 Bioscience Inc.

February 29, 2024 | globenewswire.com

Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests

February 14, 2024 | finance.yahoo.com

Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock

February 14, 2024 | globenewswire.com

Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock

February 9, 2024 | msn.com

Yield10 Bioscience Accelerates Omega-3 Camelina Launch

February 9, 2024 | finanznachrichten.de

Yield10 Bioscience, Inc.: Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program

February 8, 2024 | realmoney.thestreet.com

Yield10 Bioscience just downgraded at Lake Street, here's why

See More Headlines

Receive YTEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yield10 Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Consumer Staples
Industry: Agricultural production - crops
Sub-Industry: N/A
Current Symbol: NASDAQ:YTEN
CUSIP: N/A
CIK: 1121702
Web: www.yield10bio.com
Phone: (617) 583-1700
Fax: 617-583-1768
Employees: 30
Year Founded: 1992

Price Target and Rating

Average Stock Price Target: $3.50
High Stock Price Target: $4.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +1,272.5%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,450,000.00
Net Margins: N/A
Pretax Margin: -24,091.67%
Return on Equity: -888.81%
Return on Assets: -273.34%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.29
Quick Ratio: 0.29

Sales & Book Value

Annual Sales: $60,000.00
Price / Sales: 65.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.21) per share
Price / Book: -1.21

Miscellaneous

Outstanding Shares: 15,402,000
Free Float: 14,462,000
Market Cap: $3.93 million
Optionable: Not Optionable
Beta: 1.58

Social Links

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Oliver P. Peoples Ph.D. (Age 66)
Co-Founder, President, CEO & Director
Comp: $344.48k
Dr. Anthony J. Sinskey Ph.D. (Age 84)
Sc.D., Co-Founder & Independent Director
Comp: $62.5k
Dr. Kristi D. Snell (Age 56)
VP of Research & Chief Science Officer
Comp: $278.69k
Ms. Lynne H. Brum (Age 60)
VP of Planning & Corporate Communications and Secretary
Comp: $278.69k
Mr. Charles B. Haaser (Age 68)
VP of Finance, Chief Accounting Officer & Treasurer
Comp: $236.41k
Dr. Nicholas Renegar Ph.D.
Director of Business Analytics & Operations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

YTEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Yield10 Bioscience stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" YTEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YTEN, but not buy additional shares or sell existing shares.
View YTEN analyst ratings or view top-rated stocks.
What is Yield10 Bioscience's stock price target for 2024?: 3 Wall Street research analysts have issued 1-year target prices for Yield10 Bioscience's shares. Their YTEN share price targets range from $3.00 to $4.00. On average, they expect the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 1,272.5% from the stock's current price.
View analysts price targets for YTEN or view top-rated stocks among Wall Street analysts.
How have YTEN shares performed in 2024?: Yield10 Bioscience's stock was trading at $0.2393 at the start of the year. Since then, YTEN stock has increased by 6.6% and is now trading at $0.2550.
View the best growth stocks for 2024 here.
Are investors shorting Yield10 Bioscience?: Yield10 Bioscience saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 940,900 shares, an increase of 292.2% from the March 15th total of 239,900 shares. Based on an average daily trading volume, of 4,820,000 shares, the days-to-cover ratio is presently 0.2 days.
View Yield10 Bioscience's Short Interest.
When is Yield10 Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our YTEN earnings forecast.

How were Yield10 Bioscience's earnings last quarter?: Yield10 Bioscience, Inc. (NASDAQ:YTEN) announced its quarterly earnings data on Tuesday, November, 9th. The specialty chemicals company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.16. The specialty chemicals company earned $0.09 million during the quarter, compared to analysts' expectations of $0.22 million. During the same quarter in the prior year, the business earned ($0.87) EPS.
When did Yield10 Bioscience's stock split?: Yield10 Bioscience shares reverse split on Thursday, January 16th 2020. The 1-40 reverse split was announced on Wednesday, January 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of Yield10 Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Yield10 Bioscience investors own include KushCo (KSHB), OPKO Health (OPK), T2 Biosystems (TTOO), FuelCell Energy (FCEL), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Rigel Pharmaceuticals (RIGL), Advanced Micro Devices (AMD).
How do I buy shares of Yield10 Bioscience?: Shares of YTEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YTEN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial